CSL Seeks Disruption Of HAE Space With Monthly Prevention Product

Based on top-line Phase III data for garadacimab, CSL is preparing to submit the Factor XIIa inhibitor for US FDA approval for monthly prophylaxis of hereditary angioedema and expand the firm’s HAE franchise.

CSL heaquarters
CSL is planning to add a third HAE product to its portfolio • Source: Shutterstock

With positive top-line data for garadacimab from the Phase III VANGUARD study, CSL Limited is ready to expand its hereditary angioedema franchise with a Factor XIIa inhibitor that could offer monthly prophylaxis against the disease. While it could cannibalize from the rest of its HAE franchise, the specialty pharma told its 17 August fiscal year 2022 earnings call it hopes to disrupt the HAE space now that it has positive Phase III data for garadacimab.

Focused largely on blood plasma-derived therapies, the Australian firm is working its way through COVID-19 pandemic-related supply chain issues but...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.